Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,054 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronavirus Clear all
Completed No phase listed Observational

Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children

NCT04371315
View directory record Official record
Conditions
Corona Virus Infection, Pediatric Cancer, Adult Children, Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

NCT04351620
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580
View directory record Official record
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Cypress, California • Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

To Observe Whether Isoflurane Can Treat COVID-19 Patients

NCT04492943
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Withdrawn Phase 2 Interventional

A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia

NCT05171920
View directory record Official record
Conditions
Pneumonia
Interventions
Auxora, Placebo
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Saint Paul, Minnesota • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

NCT04865133
View directory record Official record
Conditions
COVID-19 Infection, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

IMM-BCP-01 in Mild to Moderate COVID-19

NCT05429021
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
IMM-BCP-01, Placebo
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Long Beach, California • Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

PREP (Pre-Exposure Prophylaxis) of COVID-19

NCT05461378
View directory record Official record
Conditions
Immuno-Deficiency, COVID-19
Interventions
Evusheld
Drug
Lead sponsor
Ghady Haidar
Other
Eligibility
12 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
4,891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 formulation)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
5 Years to 11 Years
Enrollment
344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
27
States / cities
Palo Alto, California • San Diego, California • Homestead, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

NCT05387278
View directory record Official record
Conditions
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Interventions
EV-Pure™ and WJ-Pure™, Placebo
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Liberty, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CareSuperb COVID-19 Antigen Test Usability

NCT05629455
View directory record Official record
Conditions
COVID-19
Interventions
CareSuperb COVID-19 Antigen Home Test Kit
Device
Lead sponsor
AccessBio, Inc.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Home Pulse Oximeter Use in Patients With COVID-19

NCT04373161
View directory record Official record
Conditions
Sars-CoV2, COVID-19, COVID
Interventions
Home Pulse Oximetry Monitoring
Device
Lead sponsor
Swedish Hospital
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))

NCT06404073
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Structured Pacing, Usual Care
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Aromatherapy on COVID-19-induced Anxiety

NCT04495842
View directory record Official record
Conditions
Stress, Covid19, Anxiety
Interventions
Essential Oil Blend, Control Blend
Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors

NCT04663945
View directory record Official record
Conditions
Covid-19, Deconditioning
Interventions
Biobehavioral Tele-rehabilitation Sessions
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 21, 2026, 9:41 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162
View directory record Official record
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

NCT04354831
View directory record Official record
Conditions
COVID-19
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Active, not recruiting Not applicable Interventional

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

NCT05167227
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Post-acute Sequelae of SARS-COV-2 Infection, Post COVID-19 Condition
Interventions
Extension for Community Healthcare Outcomes
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 21, 2026, 9:41 AM EDT